Abstract：
BACKGROUND: The use of biological therapy is becoming increasingly common in patients with hidradenitis suppurativa (HS). Levels of serum TNF-alfa and IL17 support the role of an immune system dysregulation in the pathogenesis of HS. Brodalumab targets the receptor A of IL-17, thus having a promising role in the treatment of HS.
METHODS: A multicenter retrospective observational open-label study was conducted in two tertiary hospitals. Adults with moderate to severe HS under treatment with brodalumab 210 mg at week 0, 1, 2 and then every 2 weeks were included and assessed at weeks 0 and 16 which was the median follow-up time. Demographic and disease-related variables as well as response parameters (HiSCR and IHS4) and safety data were recorded and analysed.
RESULTS: A total of 16 patients (75% males) were included in our study. 50% of patients presented an inflammatory phenotype and mean BMI was 28.37. HiSCR was achieved in 50% of patients and mean IHS4 decreased from 24.13 to 16.81 (p = 0.002). No differences were found between those who achieved HiSCR and those who did not. Grade 2 adverse events were reported in three patients with no fatal outcomes and treatment discontinuation was advised in four patients.
CONCLUSIONS: Brodalumab seems to be effective and safe in patients with moderate to severe HS, even in those that did not respond to adalimumab, which, at the moment, is the only widely approved biologic for this indication. Thus, it stands as an interesting option for the treatment of HS.
METHODS: A multicenter retrospective observational open-label study was conducted in two tertiary hospitals. Adults with moderate to severe HS under treatment with brodalumab 210 mg at week 0, 1, 2 and then every 2 weeks were included and assessed at weeks 0 and 16 which was the median follow-up time. Demographic and disease-related variables as well as response parameters (HiSCR and IHS4) and safety data were recorded and analysed.
RESULTS: A total of 16 patients (75% males) were included in our study. 50% of patients presented an inflammatory phenotype and mean BMI was 28.37. HiSCR was achieved in 50% of patients and mean IHS4 decreased from 24.13 to 16.81 (p = 0.002). No differences were found between those who achieved HiSCR and those who did not. Grade 2 adverse events were reported in three patients with no fatal outcomes and treatment discontinuation was advised in four patients.
CONCLUSIONS: Brodalumab seems to be effective and safe in patients with moderate to severe HS, even in those that did not respond to adalimumab, which, at the moment, is the only widely approved biologic for this indication. Thus, it stands as an interesting option for the treatment of HS.
摘要：
背景：在化脓性汗腺炎（HS）患者中，使用生物疗法变得越来越普遍。血清TNF-α和IL17水平支持免疫系统失调在HS发病机制中的作用。Brodalumab靶向IL-17的受体A，因此在HS的治疗中具有有希望的作用。
方法：在两家三级医院进行了一项多中心回顾性观察性开放标签研究。包括在第0、1、2周接受Brodalumab210mg治疗的中度至重度HS的成年人，然后在第0和16周进行评估，这是中位随访时间。记录并分析人口统计学和疾病相关变量以及反应参数（HiSCR和IHS4）和安全性数据。
结果：本研究共纳入16例患者（75%为男性）。50%的患者呈现炎症表型，平均BMI为28.37。50％的患者实现了HiSCR，平均IHS4从24.13降至16.81（p=0.002）。实现HiSCR的人与未实现的人之间没有差异。在3例没有致命结局的患者中报告了2级不良事件，并在4例患者中建议停止治疗。
结论：Brodalumab对中度至重度HS患者似乎有效且安全，即使在那些对阿达木单抗没有反应的人中，which,此刻,是该适应症唯一被广泛认可的生物制剂。因此，它是治疗HS的一个有趣的选择。
方法：在两家三级医院进行了一项多中心回顾性观察性开放标签研究。包括在第0、1、2周接受Brodalumab210mg治疗的中度至重度HS的成年人，然后在第0和16周进行评估，这是中位随访时间。记录并分析人口统计学和疾病相关变量以及反应参数（HiSCR和IHS4）和安全性数据。
结果：本研究共纳入16例患者（75%为男性）。50%的患者呈现炎症表型，平均BMI为28.37。50％的患者实现了HiSCR，平均IHS4从24.13降至16.81（p=0.002）。实现HiSCR的人与未实现的人之间没有差异。在3例没有致命结局的患者中报告了2级不良事件，并在4例患者中建议停止治疗。
结论：Brodalumab对中度至重度HS患者似乎有效且安全，即使在那些对阿达木单抗没有反应的人中，which,此刻,是该适应症唯一被广泛认可的生物制剂。因此，它是治疗HS的一个有趣的选择。
